do you need to stop tirzepatide before surgery GLP-1 Guidelines: When Procedures When to Resume Mounjaro After
Description
Serious adverse events are rare with both medications when used as directed by a healthcare provider

In the SURMOUNT-1 trial, participants without diabetes achieved average weight loss of 15-20% of baseline body weight over 72 weeks at the highest doses, with somewhat lower reductions observed in people with type 2 diabetes

The rationale is appealing on paper

The efficacy figures come from controlled trials in supervised patients
These results represented a breakthrough in obesity pharmacotherapy and led to FDA approval of Zepbound

Am J Ophthalmol 2021;226:22-31
